demonstrated that PD-1/PD-L1 inhibitors could restore the phagocytic ability of PD-1+ macrophages, thereby prolonging survival in preclinical colorectal cancer models in a macrophage-dependent manner (43). The gene discussed is PDCD1; the disease is colorectal cancer.